<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="t0001" orientation="portrait" position="float">
 <label>Table 1</label>
 <caption>
  <p>Registered Clinical Trials to Investigate the Efficacy and/Or Safety of Remdesivir for COVID-19</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th rowspan="1" colspan="1">Registration Number</th>
    <th rowspan="1" colspan="1">Official Title</th>
    <th rowspan="1" colspan="1">Status</th>
    <th rowspan="1" colspan="1">Country</th>
    <th rowspan="1" colspan="1">Estimated Study Completion Date</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="1" colspan="1">NCT04257656</td>
    <td rowspan="1" colspan="1">A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of remdesivir in hospitalized adult patients with severe COVID-19</td>
    <td rowspan="1" colspan="1">Terminated</td>
    <td rowspan="1" colspan="1">China</td>
    <td rowspan="1" colspan="1">April 10, 2020</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">NCT04365725</td>
    <td rowspan="1" colspan="1">A multicenter, retrospective study of the effects of remdesivir in the treatment of severe COVID-19 infections</td>
    <td rowspan="1" colspan="1">Recruiting</td>
    <td rowspan="1" colspan="1">France</td>
    <td rowspan="1" colspan="1">June 2020</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">NCT04302766</td>
    <td rowspan="1" colspan="1">An intermediate-size patient population expanded access treatment protocol for coronavirus disease 2019 (COVID-19) using remdesivir (RDV; GS-5734™)</td>
    <td rowspan="1" colspan="1">Available</td>
    <td rowspan="1" colspan="1">–</td>
    <td rowspan="1" colspan="1">–</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">NCT04252664</td>
    <td rowspan="1" colspan="1">A phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of remdesivir in hospitalized adult patients with mild and moderate COVID-19</td>
    <td rowspan="1" colspan="1">Suspended</td>
    <td rowspan="1" colspan="1">China</td>
    <td rowspan="1" colspan="1">April 27, 2020</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">NCT04323761</td>
    <td rowspan="1" colspan="1">Expanded access treatment protocol: remdesivir (RDV; GS-5734) for the treatment of SARS-CoV-2 (CoV) infection</td>
    <td rowspan="1" colspan="1">Available</td>
    <td rowspan="1" colspan="1">–</td>
    <td rowspan="1" colspan="1">–</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">NCT04410354</td>
    <td rowspan="1" colspan="1">A phase 2, randomized, double-blind, placebo-controlled study of the efficacy and safety of oral merimepodib in combination with intravenous remdesivir in adult patients with advanced coronavirus disease 2019 (COVID-19)</td>
    <td rowspan="1" colspan="1">Recruiting</td>
    <td rowspan="1" colspan="1">USA</td>
    <td rowspan="1" colspan="1">August 2020</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">NCT04292730</td>
    <td rowspan="1" colspan="1">A phase 3, randomized study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with severe COVID-19</td>
    <td rowspan="1" colspan="1">Active, not recruiting</td>
    <td rowspan="1" colspan="1">–</td>
    <td rowspan="1" colspan="1">June 2020</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">NCT04409262</td>
    <td rowspan="1" colspan="1">A phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with severe COVID-19 pneumonia</td>
    <td rowspan="1" colspan="1">Recruiting</td>
    <td rowspan="1" colspan="1">–</td>
    <td rowspan="1" colspan="1">July 31, 2020</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">NCT04431453</td>
    <td rowspan="1" colspan="1">A phase 2/3, single-arm, open-label study to evaluate the safety, tolerability, pharmacokinetics and efficacy of remdesivir (GS-5734™) in participants from birth to &lt;18 years of age with COVID-19</td>
    <td rowspan="1" colspan="1">Not yet recruiting</td>
    <td rowspan="1" colspan="1">–</td>
    <td rowspan="1" colspan="1">December 2020</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">NCT04330690</td>
    <td rowspan="1" colspan="1">A multicenter, adaptive, randomized, open-label, controlled clinical trial of the safety and efficacy of investigational therapeutics for COVID-19 in hospitalized patients (CATCO: Canadian Treatments for COVID-19), in conjunction with the Public Health Emergency SOLIDARITY Trial (World Health Organization)</td>
    <td rowspan="1" colspan="1">Recruiting</td>
    <td rowspan="1" colspan="1">Canada</td>
    <td rowspan="1" colspan="1">May 18, 2022</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
